The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder cancer, and ovarian cancer. The trials showed significant survival benefits ...

Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in patients with ...

A secondary analysis of the phase 3 KEYNOTE-716 trial finds that adjuvant Keytruda improves recurrence-free survival without increasing the risk of new primary melanoma and may reduce non-melanoma ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

ImmunityBio Executive Chairman Patrick Soon-Shiong criticized the FDA for applying tougher approval standards to Anktiva than ...

Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data. Read more here.

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved ...